Journal of Developing Drugs
Open Access
ISSN: 2329-6631
ISSN: 2329-6631
Alex Chang ZOU
School of Biomedical Sciences
The Chinese University of Hong Kong, China
Alex Chang ZOU, is a qualified physician and treated both emergency and in-hospital patients with surgical disorders as in Dong Rui Hospital, Nanjing, China. He is presently working as Deputy Director in Clinical Research Centre. His previous research work includes: 1. Selection and validation of esophageal cancer cell targeting phage-displayed peptides. 2. Dose-effect curve study and new applications development of human recombinant endostatin. 3. Preclinical study of an anti-VEGF monoclonal antibody drug. Functional study of estrogen-related receptor alpha in prostate cancer. 4. Estrogen-related receptor alpha in Castration-Resistance Prostate Cancer. He also provided an original idea and prepared preliminary data for the grant applying and found that ERRï¡ overexpression in prostate cancer contribute to its Bicalutamide-resistance and androgen independent growth both in vitro and in vivo.
Alex Chang ZOU, is a qualified physician and treated both emergency and in-hospital patients with surgical disorders as in Dong Rui Hospital, Nanjing, China. He is presently working as Deputy Director in Clinical Research Centre. His previous research work includes: 1. Selection and validation of esophageal cancer cell targeting phage-displayed peptides. 2. Dose-effect curve study and new applications development of human recombinant endostatin. 3. Preclinical study of an anti-VEGF monoclonal antibody drug. Functional study of estrogen-related receptor alpha in prostate cancer. 4. Estrogen-related receptor alpha in Castration-Resistance Prostate Cancer. He also provided an original idea and prepared preliminary data for the grant applying and found that ERRï¡ overexpression in prostate cancer contribute to its Bicalutamide-resistance and androgen independent growth both in vitro and in vivo.